Porter Details Future Directions For Treating Patients With KRAS G12C-Mutated NSCLC

Jason Porter, MD, discusses the progress in the development of treatment options for patients with KRAS G12C-mutated non–small cell lung cancer.

Related Keywords

Memphis ,Tennessee ,United States ,Jason Porter ,Research Institute In Memphis ,Onclive Institutional Perspectives ,Lung Cancer Disease Research Group ,West Cancer Center ,Research Institute ,Lung Cancer ,D ,Nsclc ,Onclive Institutional Perspectives In Cancer ,Kras Mutated Nsclc ,